MPMaitreyee Panda

Maitreyee Panda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maitreyee Panda has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Follicular Lesions in Pediatric Dermatology: A Comprehensive Review and Approach Based on Clinical, Dermoscopic, and Histopathological Evaluation and Treatment

    by Shreya K. Gowda, Rahul Mahajan, Maitreyee Panda, Biswanath Behera, Madhusmita Sethy, Pavithra Ayyanar

    Pediatric dermatoses presenting as follicular papules are common entities encountered in clinical practice. These are a heterogeneous group of disorders of infectious or noninfectious origin that commonly present as regularly spaced, small papules with or without perifollicular inflammation. Inflammatory causes include follicular eczema, pityriasis rubra pilaris, lichen nitidus, follicular seborrheic dermatitis, keratosis pilaris and its variants, keratosis circumscripta, follicular psoriasis, lichen spinulosus, follicular lichen planus, follicular mucinosis, perforating folliculitis, follicular porokeratosis, and follicular dermographism. These conditions may arise due to filaggrin mutations, keratinization defects, autoimmunity, or microbial triggers. Nutritional causes include phrynoderma and scurvy, while connective tissue diseases such as dermatomyositis and chronic cutaneous lupus erythematosus are autoimmune. Additional categories include infectious, genetic, hormonal, environmental, frictional, malignant, nevus-related, iatrogenic, and idiopathic entities. An early and accurate diagnosis is essential for proper management and reducing disease-associated apprehension in children and/or their parents. This review attempts to describe the role of history taking and clinical examination, including morphology, location, pattern of distribution, and associated features, while dealing with a child with follicular-based papules. In addition, it delineates the role of dermoscopy and pathological examination in reaching a correct diagnosis. Furthermore, it describes the available treatment options and disease course of various follicle-based dermatoses.

  • Open Access

    Therapeutic Efficacy and Safety of Oral Cyclosporine and that of Oral Prednisolone in the Management of Refractory Oral Lichen Planus: A Comparative Study

    by Adithya Prakash, Ajaya Kumar Jena, Anil Kumar Panda, Maitreyee Panda

    Background: Oral lichen planus (OLP) is a chronic autoimmune disorder of the oral mucosa that often requires long-term treatment due to its relapsing nature. While corticosteroids remain the first-line therapy, refractory cases necessitate alternative treatments. Cyclosporine, an immunosuppressant, has shown potential efficacy in OLP management, but lacks comparative studies with oral prednisolone, a commonly used systemic corticosteroid. Aim and Objective: To compare the efficacy and safety of oral cyclosporine versus oral prednisolone in managing refractory oral lichen planus. Patients and Methods: A prospective, randomized, controlled trial was conducted at a tertiary care hospital in eastern India, enrolling patients with refractory OLP. Participants were randomly assigned to receive either oral cyclosporine or oral prednisolone. Efficacy was evaluated using improvement in the oral disease severity score (ODSS), dermatology life quality index (DLQI), and visual analogue scale (VAS), while safety was assessed by monitoring adverse events, laboratory markers, and patient tolerance. Results: Both treatment groups showed significant improvement in ODSS and DLQI scores ( P < 0.05). The cyclosporine group had a 92.7% reduction in ODSS compared to 88.8% in prednisolone group( P =0.03), while DLQI improved by 84.8% versus 78.08% ( P =0.04). Prednisolone was associated with higher rates of hyperglycemia and hypertension, whereas cyclosporine posed a risk of nephrotoxicity and relapses. Limitations: A short follow-up period and a small sample size were limitations. Conclusion: To conclude, cyclosporine appears to be an effective and safe alternative to prednisolone, warranting further studies with a larger sample size and extended follow-up.

  • Open Access

    Efficacy and Safety of Injection Secukinumab in Patients of Pediatric Erythrodermic Psoriasis

    by Tanisha Nayak, Nibedita Dixit, Anil K. Panda, Maitreyee Panda

  • Open Access

    Red Scrotum Syndrome Responding to Doxycycline: A Report of Two Cases with a Review of the Literature

    by Sri Dantuluri M. Varma, Ananya Pramanik, Akash Agarwal, Maitreyee Panda

  • Open Access

    Target-specific therapeutic assessment of repurposed drug candidates for oral lichen planus: a network pharmacology-molecular dynamics simulation guided investigation

    by Alaka Sahoo, Shasank Sekhar Swain, Satya Ranjan Singh, Atala Bihari Jena, Sudhir Kumar Paidesetty, Asim K. Duttaroy, Maitreyee Panda

    Background: Oral lichen planus (OLP) is a chronic mucocutaneous autoimmune skin disease without a proper pathophysiology and approved therapy. As a result, several repurposed drugs have been used in clinical practice, and it remains unclear which one holds greater potential. Aim: The present study employs a network pharmacology to explore the disease biology and further investigate the target-specific binding efficacy of repurposed drugs. Materials and methods: Twenty-eight repurposed drug’s ( D1 - D28 ) efficacies against twelve targets were investigated using PyRx 0.8-AutoDock 4.2 software. Further, drug stability and reactivity were studied using molecular dynamics (MD) simulation at 200 ns, Gibbs free energy, frontier molecular orbital theory, and structural activity relationship. Results: The above computational investigation suggested betamethasone ( D2 /BETA) and triamcinolone acetonide ( D28 /TACA) are two potential drugs, predominantly demonstrating higher binding efficacy against the glucocorticoid receptor (GR). Further, MD simulation, free-energy calculation revealed that D28/ TACA was comparatively more stable than D2 /BETA. Conclusion: The network pharmacology explored possible drug targets for drug discovery and showed that D28/ TACA is a more effective treatment option among repurposed drugs.


  • Anti‐Inflammatory and Immunomodulatory Phytochemicals for Management of Oral Lichen Planus: A Multi‐Omics System Biology and Experimental Assessment

    by Alaka Sahoo, Shasank S. Swain, Satya R. Singh, Ajaya K. Jena, Sudhir K. Paidesetty, Maitreyee Panda

    Oral lichen planus (OLP) is a chronic autoimmune inflammatory disorder where the exact pathophysiology remains unclear, posing challenges to effective treatment. The accumulative evidence suggested that anti‐inflammatory and immunomodulatory phytochemicals showed alternative therapeutic effects. Accordingly, the present study selected 28 multimodal phytochemicals (P1 to P28) and further assessed their potency and drug‐ability using computer‐aided drug design (CADD) and experimental methods. At first, the putative targets for OLP were selected through network pharmacology, and then molecular docking scores with predicted drug‐ability profiles recommended that P12 (epicatechin gallate/ECG) be the lead candidate among all. Furthermore, the protein–ligand stability of ECG against the nonsteroidal target cyclooxygenase‐2 (COX‐2) and the steroidal target glucocorticoid receptor (GR) was investigated using molecular dynamics (MD) simulations over 200 ns, and free energy calculations (MM/PBSA) were performed with GROMACS‐2020 software. The nontoxic dose for ECG was observed to be > 100 µM in three cell lines (HEK293, Huh7, and THP‐1). The gene expression results demonstrated that the COX‐2 and the proinflammatory cytokine IL‐1β significantly reduced, and the anti‐inflammatory cytokine IL‐10 slightly increased in a concentration‐dependent manner in inflammation‐induced (LPS‐treated) THP‐1 cells. Overall, the systematic computational and experimental results suggested that ECG could be a potent therapeutic option for managing OLP among the listed treatments.


  • Open Access

    Spectrum of Dermatology Referrals from the Pediatric Cancer Unit: A Prospective Observational Study

    by Akash Agarwal, Saroj Prasad Panda, Maitreyee Panda, Ajaya Kumar Jena

    Background: Dermatological manifestation in pediatric cancers can occur as part of primary malignancy or cutaneous metastasis, or chemotherapy-associated side-effects. Aim: The aim of this study was to evaluate the cutaneous manifestations in pediatric malignancies and their impact on management. Materials and Methods: A prospective observational study was conducted at a tertiary center between September 2019 and March 2022. All pediatric patients with confirmed malignancy having a cutaneous manifestation were screened for eligibility and their data were recorded. The data were analyzed using SPSS software. Results: Data from 117 patients with a mean age of 7.53 ± 4.41 years were recorded. Twenty-four patients (20.5%) had cutaneous manifestations of an initial malignancy presentation. Nineteen out of 88 patients with acute leukemia (21.5%) had purpuric lesions as the initial presentation. A total of 257 chemotherapy-related skin manifestations were noted in 117 patients with infections being the most common ( n = 85, 72.64%), followed by hair changes ( n = 59; 50.42%), nail changes ( n = 39; 33.33%), and mucosal changes ( n = 36; 30.76%). Oral mucositis was the most common mucosal side effect noted in 22 patients, with the majority having underlying hematological malignancy (20/22) and methotrexate-based regimen being the most common culprit (17/22). 44 and 57 out of the total 257 cutaneous manifestations warranted hospitalization and further chemotherapy modification, respectively, with oral mucositis Grade 3 or 4 ( n = 12) and varicella ( n = 10) being the most common culprits. Conclusion: Our study represents one of the largest study evaluating the cutaneous manifestations of pediatric malignancies including both and chemotherapy-associated. In addition to understanding the various cutaneous manifestations, it is paramount to manage these presentations promptly to reduce disease-related morbidity.


  • Evidence‐Based Recommendations for Managing Atopic Dermatitis in Pediatric Patients: A Systematic Review and Meta‐Analysis From the Pediatric Dermatology Special Interest Group of IADVL

    by Rahul Mahajan, Rashmi Sarkar, Maitreyee Panda, Bhumesh Kumar Katakam, Jigna Padhiyar, Thiruveedhula Haritha, Liza Mohapatra, Nibedita Patro, Rita Vora, Shazia Shah, et al.

    Background: Atopic dermatitis (AD) is the most common inflammatory skin disease in the pediatric age group, affecting 15%–20% of children globally. Initial treatment modes include hydration, occlusive topical medicines, antimicrobial treatment, phototherapy, and systemic immune suppressants in the case of severe to moderate refractory AD. However, there is a lack of head‐to‐head studies on the choice of topical and systemic therapies for moderate to severe AD in the pediatric age group.Objective: This systematic review aimed to determine the efficacy and safety of topical and systemic treatments for moderate‐to‐severe AD in the pediatric age group.Method: A systematic review was performed following the Preferred Reporting Items for Systemic Reviews and Meta‐Analyses (PRISMA) guidelines. A search of articles was done from PubMed and Google Scholar from 1975 to 2023.Results: We found a total of 1114 possible clinical trials. Of these, 68 articles fulfilled the eligibility criteria. Thirty‐four articles discussed topical therapies, which included corticosteroids, calcineurin inhibitors, and emollients, and 34 articles were about systemic therapies, consisting of cyclosporine, dupilumab, upadacitinib, thymopentin, omalizumab, antihistamines, probiotics, and others. Out of 68 studies, 41 were randomized controlled trials.Conclusion: Based on the study results, we conclude that topical steroids and calcineurin inhibitors are effective and safe in mild to moderate pediatric AD. It was also demonstrated that while systemic monotherapy with dupilumab (in age groups younger than 6 months) and JAK inhibitors (like abrocitinib and upadacitinib in those younger than 12 years) is highly effective in rapidly reducing severity scores, their high cost and limited availability restrict their use in countries like India. In such settings, cyclosporine (and sometimes oral prednisolone in tapering doses over 2 weeks) is still recommended as a first‐line therapy in severe AD while planning for steroid‐sparing agents.


  • Open Access

    Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study

    by Farheen Begum, Sasmita Mishra, Ajaya K. Jena, Maitreyee Panda

    Background: Alopecia areata (AA) is an autoimmune, T-cell-mediated disorder manifesting as non-scarring alopecia. Treatment consists of corticosteroids, calcineurin inhibitors, prostaglandin analogs, minoxidil, anthralin, vitamin D analogs, and JAK STAT inhibitors. Despite several treatment options, personal opinions regarding the safety and efficacy of a particular treatment are highly variable. This has led the management of AA to be quite challenging. Aim: To compare the efficacy and safety between the three molecules, namely mometasone 0.1% ointment, calcipotriol 0.005% ointment, and tacrolimus 0.1% ointment, in localized AA. Patients and Methods: Patients were randomized into three groups, and topical medications were dispensed for each group in unlabeled tubes. Lesional photographs, dermoscopic images, Severity of Alopecia Tool (SALT) scoring, hair pull test, and Dermatology Life Quality Index questionnaires were done at the baseline visit and at every follow-up visit at 4 weeks and 8 weeks from the baseline visit. Results: At the end of 8 weeks, both mometasone and calcipotriol groups had a significant decrease in their SALT scores (<0.001), but the tacrolimus group did not show any significant change in parameters at the end of the study. Limitations: The main drawback is that there was no control group and the vehicle dispensed was ointment formulation, which may have penetration issues. The lack of long-term follow-up is also a limitation of this study. Conclusion: Both mometasone and calcipotriol formulations were found to be effective in the treatment of localized stable AA; however, calcipotriol preparation was associated with minimal side effects.